Engflag

Axel

Quick links to important sections

Axel

Axel_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Axel

Quick Facts

Property Description
Active Ingredients Aceclofenac and Triclosan
Form Topical Preparation (e.g., Gel or Cream)
Pharmacological Class Combination NSAID and Antiseptic
Route of Administration Cutaneous (Applied to the skin)
Origin Synthetic

What Type of Medicine is Axel and What is it Made Of?

Axel is classified as a combination drug formulated for topical use that acts as an anti-inflammatory, pain-relieving, and antiseptic preparation. This product is synthetic in origin and contains two distinct active ingredients: Aceclofenac and Triclosan.

Aceclofenac is the key component and belongs to the class of medicines known as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), commonly identified as an acetic acid derivative. This ingredient is clinically recognized for its ability to reduce inflammation, as its primary function is to inhibit inflammation-causing substances. Triclosan is the second active ingredient, included as an antiseptic/antibacterial agent to inhibit the growth of bacteria and fungi on the skin surface.

How Does Axel’s Dual-Action Composition Benefit Me?

The dual-action nature of Axel is designed for comprehensive relief in localized conditions. The NSAID component works to address the root cause of discomfort by reducing inflammation, while the antiseptic provides a complementary protective function. This specific formulation is often utilized when localized pain or inflammation may benefit from simultaneous antimicrobial surface protection.

The inclusion of an NSAID in a topical form is a therapeutic approach intended for localized pain and swelling management. This dual approach is particularly useful in scenarios where a patient needs a powerful topical analgesic along with routine antimicrobial surface support.

Why is Axel Formulated as a Topical Preparation?

Axel is supplied as a topical preparation to ensure the medication’s effects are focused efficiently at the site of application. The cutaneous route of administration is preferred for superficial pain and inflammatory conditions, as it avoids systemic processing. This targeted delivery allows the active components to work locally, which may minimize the risk of some common side effects associated with oral NSAID intake.

What side effects are possible with Axel?

Official Safety Profile and Adverse Reactions

The safety characteristics of Axel, a topical preparation containing Aceclofenac (NSAID) and Triclosan (Antiseptic), are officially classified based on the risk profiles of its active components, with a primary focus on local reactions.

Most reported adverse effects are dermatological, reflecting the cutaneous route of administration. These are primarily categorized as Common and include localized events such as rash, pruritus (itching), erythema (reddening), and various forms of dermatitis (including eczema and contact dermatitis). Less frequently, a burning sensation or dry skin at the application site may be reported, though these are sometimes classified as having an unknown frequency in regulatory documents.

Serious Adverse Reactions associated with the NSAID class are considered Very Rare for the topical formulation but are mandatory inclusions in the official labeling. These include systemic allergic events like anaphylactic reactions and severe, potentially fatal cutaneous reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The labeling notes that serious skin reactions often appear early in the course of therapy.

Population-Specific Safety Constraints exist, with use being contraindicated in the third trimester of pregnancy due to risk of fetal cardiotoxicity. The medication is also restricted in individuals with a known history of NSAID-induced asthma or hypersensitivity. The possibility of systemic side effects, though low, increases with prolonged use or application over large skin surface areas, according to official safety documentation.

Overdose and Emergency Response

The overdose profile for Axel is defined by the systemic risks associated with the Aceclofenac component, typically following accidental oral ingestion or significant excessive topical application. Regulatory documents state that common overdose manifestations include gastrointestinal disturbances such as nausea, vomiting, and epigastric pain, in addition to central nervous system effects like dizziness and drowsiness.

Manifestations Severe Outcomes
Nausea, Vomiting, Dizziness Gastrointestinal bleeding/perforation
Epigastric Pain, Drowsiness Acute renal failure, Seizures, Stroke

Official regulatory sources classify overdose as potentially resulting in life-threatening outcomes, specifically listing the risk of fatal gastrointestinal bleeding and serious cardiovascular thrombotic events. Elderly patients and individuals with pre-existing impaired renal or cardiac function are officially noted to have increased risks for severe complications. The labeling mandates that patients seek immediate medical attention for symptoms indicative of a severe adverse event, such as chest pain, sudden weakness, or signs of an anaphylactic reaction. As no specific antidote is known, the required management is strictly symptomatic and supportive treatment, often requiring close hospital monitoring and laboratory checks of renal function. This official guidance dictates that urgent medical evaluation is necessary when severe symptoms occur.

Therapeutic Uses of Axel

What Axel Treats: Main Uses and Benefits

Axel is generally used across conditions presenting with localized discomfort, and is applied in addressing symptom clusters that may involve pain, swelling, and tenderness associated with soft tissue and joint disorders. This class of medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as strains, sprains, and contusions (bruises), and may be part of the symptomatic management for chronic localized conditions like osteoarthritis. This application generally provides support that assists with maintaining functional stability during symptomatic periods and helps ease the overall symptom load.

This medication is commonly used when short-term symptomatic assistance is needed in contexts where localized inflammatory pain and the requirement for antiseptic protection of the skin surface are both relevant. The dual-action formula plays a role in managing symptoms that create noticeable physiological strain, which may contribute to improved comfort while offering surface antiseptic support.

“This class of medication is relevant when supportive symptom management is appropriate in contexts involving inflammatory or irritative processes.”

Quick Fact: Relief for Localized Symptoms
Therapeutic Domain Musculoskeletal pain and inflammation
Key Symptom Axes Localized tenderness, swelling, and physical discomfort
Key Patient Benefit Symptomatic relief and surface antiseptic support
Usage Context Acute injuries and chronic localized joint flares

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility for using Axel (Topical Aceclofenac/Triclosan) is defined by official regulatory documents, primarily based on the systemic risks associated with its NSAID component, Aceclofenac.

Category Regulatory Status
Contraindicated Populations Must Not Use: Patients with known NSAID hypersensitivity (including aspirin-sensitive asthma), severe heart, renal, or hepatic failure, active peptic ulcers or bleeding, and women in the third trimester of pregnancy (from 30 weeks) [1.1, 1.2, 2.1].
Age-Group Rules Adults are eligible. Use is not recommended in children and adolescents (under 18) due to insufficient clinical safety data [1.3]. Older adults are permitted use but require caution and surveillance due to increased risk factors [2.2].
Conditional Use Patients with mild to moderate renal or hepatic impairment may be permitted use but require close medical surveillance [1.1]. Application to open wounds or damaged skin is strictly contraindicated [1.2].
Pregnancy/Lactation Contraindicated in the third trimester [2.1]. Not recommended during the first two trimesters, while breastfeeding, or for women attempting to conceive [1.1, 2.4].

The structure ensures that patients with severe pre-existing systemic conditions or a history of NSAID-related allergies are formally excluded from using this medicine. Eligibility is constrained by specific physiological conditions and age limitations as mandated by governmental health authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Axel is defined by the systemic exposure potential of its Aceclofenac component, which is a Nonsteroidal Anti-Inflammatory Drug (NSAID). No systemic drug-drug interactions are formally documented for the topical Triclosan component.

Interaction Restrictions and Risks

Regulatory documents specify several Prohibited Combinations: co-administration with other NSAIDs or Acetylsalicylic Acid (Aspirin) is restricted due to an increased risk of adverse events.

A Timing-Separation Rule applies to Mifepristone: NSAIDs must not be used for 8 to 12 days after its administration, as documented in regulatory labeling, to avoid reducing its effect.

Exposure-Altering Interactions (Pharmacokinetic Risk): Co-administration may increase the plasma concentrations of certain medicines, including Lithium, Digoxin, and Methotrexate, primarily through reduced renal clearance pathways.

Additive Risk of Toxicity (Pharmacodynamic Risk): Combining Axel with substances like Anticoagulants, Corticosteroids, Anti-Platelet Agents, or Selective Serotonin Reuptake Inhibitors (SSRIs) may enhance the risk of bleeding or gastrointestinal ulceration. Additionally, co-use with Antihypertensives (ACE-inhibitors/ARBs) or Diuretics may increase the risk of nephrotoxicity. Alcohol co-consumption may increase the risk of serious gastrointestinal adverse events.

Population-Specific Notes: Interaction severity, particularly the risk of acute renal insufficiency when co-administered with ACE-inhibitors, is noted to be heightened in Elderly Patients and those with officially documented Compromised Renal Function.

Mechanism of Action

Enzyme-Mediated Modulation of Inflammatory Signals

Axel's primary physiological effect begins with Aceclofenac, which acts as a competitive inhibitor of Cyclooxygenase (COX) enzymes, particularly COX-2. By blocking this enzyme, the drug interrupts the arachidonic acid cascade, the pathway responsible for generating prostaglandins—key mediators within the inflammatory and nociceptive signaling pathways. This process results in the modulation of peripheral nociceptor sensitivity and limits local vasodilation, resulting in the localized modulation of physiological processes.

Targeted Disruption of Microbial Metabolism

The second component, Triclosan, exerts its influence by engaging mechanisms that modulate surface microbial colonization mechanisms. Its core mechanism involves inhibiting the bacterial enzyme FabI (enoyl-acyl carrier protein reductase), which is essential for bacterial fatty acid synthesis. This targeted pathway interference prevents microbial proliferation and, at higher local concentrations, physically disrupts the bacterial cell membrane, which results in localized surface antimicrobial activity and functionally coordinates with the host-focused mechanism of inflammation modulation.

Functional Complementarity and Dual-Action

These two distinct mechanisms work with functional complementarity at the application site: one system addresses the host’s inflammatory and pain signaling pathways, while the other addresses the microbial viability within the local tissue environment. The drug engages these separate regulatory systems to effect modulation across distinct physiological systems through a two-pronged, mechanism-driven approach.

Dosage and Administration Information

The administration of Axel, a topical preparation containing Aceclofenac and Triclosan, follows standard principles for cutaneous drug delivery.

Administration Scope

Instruction Detail
Route of administration Cutaneous application only, applied directly to the skin surface.
Dosing schedule The standard approach is to apply a sufficient thin layer of the gel to the localized affected area, typically correlating to 2 to 4 grams for larger joints.
Frequency pattern The preparation is generally applied 3 to 4 times per day (TID or QID) to ensure continuous localized symptomatic support.
Age-group administration rules Use is not recommended in children or adolescents under 14 years due to a lack of specific data for topical NSAIDs in this age group.
Special procedural conditions The product must be applied to intact, healthy skin, strictly avoiding open wounds or mucous membranes. Use in conjunction with occlusive dressings is restricted.

Connection to the Overall Use Protocol

This protocol defines a standardized, non-systemic method for utilizing the medication. Standard protocols provide that the preparation is intended for short-term use, with the duration of application typically being subject to re-evaluation after 7 days if symptom support is ongoing. This approach reflects the dosing standards for Aceclofenac combination topical gels.

Recent Clinical Evidence

Research evidence / Overview of studies for Axel

The research landscape for Axel, a topical combination of the NSAID Aceclofenac and the antiseptic Triclosan, draws from two separate evidence bases. The primary evidence reflects studies on topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) used to examine outcomes related to physical discomfort and inflammatory states, while the secondary evidence involves laboratory and clinical evaluations of the antiseptic agent. The following summary outlines the existing research according to official and peer-reviewed sources.

Evidence for Use in Localized Pain and Inflammation

Research for the NSAID component of this medicine was primarily conducted through randomized controlled trials (RCTs) and comprehensive systematic reviews that examined the use of topical NSAIDs for localized discomfort. These studies were applied in research contexts involving fluctuating or unstable symptoms, such as acute soft tissue injuries (strains and sprains) and chronic joint disorders like osteoarthritis. The studies monitored patient-reported outcomes, focusing on perceived discomfort and changes reflecting daily functioning or activity level.

The majority of evaluation studies for topical NSAIDs focus on short- to intermediate-term outcomes, typically up to 12 weeks. While numerous studies describe patterns observed when topical NSAIDs were evaluated for these conditions, specific comparative evidence for the topical Aceclofenac formulation itself remains limited compared to the extensive data available for related NSAIDs, such as topical Diclofenac or Ketoprofen.

Evidence for the Surface Antiseptic Component

Research has explored the second component, Triclosan, for its potential in inhibiting microbial growth, primarily through laboratory (in vitro) studies. These studies described inhibition of growth against a broad range of common microorganisms under controlled conditions.

However, when considering its use in general topical use for localized pain, regulatory reviews suggest that the certainty remains low. Official reviews have also stated that the certainty remains low regarding the clinical benefit of the antiseptic ingredient in general topical products compared to alternatives. Research on the dual-action composition of the specific combination product (Aceclofenac plus Triclosan) is still emerging.

What Remains Uncertain in the Research Landscape

Key research limitation frames include the scarcity of data from trials that directly examine the combined patterns of response when Aceclofenac and Triclosan are used together compared to the NSAID component alone. Furthermore, comparative evidence is lacking for head-to-head trials between this specific topical Aceclofenac formulation and other similar topical NSAID products. The durability or persistence of outcomes related to physical discomfort beyond the initial three-month mark are not fully established in the research literature.

Key Studies & References Diclofenac Topical (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Axel (FAQ)

Q: Why is this drug causing a dry cough?

A: According to official product information, a dry cough is a reported adverse reaction when taking medications that work as Angiotensin-Converting Enzyme (ACE) inhibitors. This is considered related to how the medicine works in the body. Patients who experience this side effect are encouraged to discuss it with a healthcare professional.

Q: Can I take this drug with ibuprofen for pain?

A: Official documents indicate that combining Axel with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may carry risks. This combination may potentially increase the risk of reduced kidney function. Furthermore, the blood pressure-lowering effect of Axel may be less effective when taken concurrently with NSAIDs.

Q: Does it make you sleepy or affect my driving?

A: The regulatory information lists dizziness and fatigue as potential common side effects of Axel. These effects may impact the ability to safely drive or operate machinery. This risk may be more noticeable when treatment is first started or following a change in dosage.

Q: Can I stop taking this medicine if my blood pressure is normal now?

A: Axel is intended for the long-term, chronic management of conditions like hypertension or heart failure. The official product information focuses on administration and does not provide directions for discontinuation. Discontinuation or changes to chronic therapy are generally not recommended without the supervision of a healthcare professional.

How should Axel be stored and disposed of?

How to Store and Dispose of Axel (Aceclofenac/Triclosan) Topical Preparation

Official regulatory labeling dictates strict conditions for the storage and disposal of Axel to maintain its stability and ensure environmental safety.

Storage Requirements

Axel must be stored at a temperature not exceeding 25 C (77 F) and should be kept in a dry place. It is mandatory to protect the preparation from light and prohibit freezing. The product must remain in its tightly closed, original container and be secured out of the sight and reach of children.

Disposal Instructions

Unused or expired Axel must not be discarded with household trash or disposed of by pouring it into the wastewater system (sink or toilet). Disposal must adhere strictly to local requirements and directions provided by a pharmacist or an authorized pharmaceutical waste service.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Axel found in:

A-Z Index: